Avita Medical (ASX:AVH) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects.
Avita’s patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient’s own skin.
The Company’s regenerative product portfolio includes ReCell® for burns & plastic reconstructive procedures, ReGenerCell® for chronic wounds and ReNovaCell® of restoration of pigmentation and cosmesis.
ReCell®, ReGenerCell® and ReNovaCell® are patented, CE‐marked for Europe. ReCell® is TGA‐registered in Australia, and CFDA‐cleared in China.
In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. trial is well underway aimed at securing FDA approval.